

TES-002

REPORTED June 25, 2026

CLIENT

NAME Peptide Test Canada
CONTACT PTC Operations
EMAIL info@peptidetestcanada.ca
ADDRESS Canada

SCAN TO VERIFY



PTC-SMQGNUXG

END CUSTOMER

NAME NextPhase Biolabs
EMAIL Info@nextphasebiolabs.ca
PHONE
ADDRESS Edmonton, Alberta, Canada

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID:	TES-002	Total Mass:	72.2 mg	CAS:	218949-48-5
Compound:	Tesamorelin	Appearance:	Lyophilized powder	Formula:	C₂₂₁H₃₆₆N₇₂O₆₇S
Report No.:	COA-2026-SC-00060	Received:	06/15/2026	Mol Weight:	5135.9 g/mol
Lot Number:	COA-2026-SC-00060	Analyzed:	06/25/2026		

§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	Tesamorelin	Tesamorelin	PASS
Quantity:	5.00 mg	4.86 mg	
Purity:	≥ 98 %	98.20 %	

§ 03 LC-MS/MS Detail


METHOD B · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+5H]⁵⁺

1028.70 Da

Quantifier transition ● MRM

1028.70 > 136.10 CE 30 V



ROLE	TRANSITION	CE
● Quantifier	1028.7 > 136.1	30 V
■ Qualifier	1028.7 > 120.1	33 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 µm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

This report documents **analytical results only**. Provided for **research purposes only**; not a drug-release or quality certification. SideChain Analytics makes no representation regarding resale, clinical use, or human / veterinary administration of the material.